Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bach

Showing results (351-360 of 363) with videos related to

Pageof 37
Sort By:
Circulation. Cardiovascular Interventions|July 13, 2021
Transradial Access for High-Risk Percutaneous Coronary Intervention: Implications of the Risk-Treatment ParadoxAmit P Amin, Sunil V Rao, Arnold H Seto, et al.
Journal of Medical Genetics|April 3, 2004
Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis IIIA Raas-Rothschild, R Bargal, O Goldman, et al.
European Heart Journal|April 1, 2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan K James, Richard G Bach, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 8, 2014
Conversations in cardiology: bridging antiplatelet therapy before surgeryMorton J Kern, Robert J Applegate, Malcolm Bell, et al.
The American Journal of Cardiology|December 9, 2019
Improving Care Pathways for Acute Coronary Syndrome: Patients Undergoing Percutaneous Coronary InterventionAmit P Amin, John A Spertus, Hemant Kulkarni, et al.
Journal of the American College of Cardiology|May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyCarolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 14, 2013
Conversation in cardiology: should FFR and IVUS be counted as PCI?Morton Kern, Robert Applegate, Richard G Bach, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
Pageof 37

Showing results (351-360 of 363) with videos related to

Sort By:
Pageof 37
Circulation. Cardiovascular Interventions|July 13, 2021
Transradial Access for High-Risk Percutaneous Coronary Intervention: Implications of the Risk-Treatment ParadoxAmit P Amin, Sunil V Rao, Arnold H Seto, et al.
Journal of Medical Genetics|April 3, 2004
Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis IIIA Raas-Rothschild, R Bargal, O Goldman, et al.
European Heart Journal|April 1, 2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan K James, Richard G Bach, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 8, 2014
Conversations in cardiology: bridging antiplatelet therapy before surgeryMorton J Kern, Robert J Applegate, Malcolm Bell, et al.
The American Journal of Cardiology|December 9, 2019
Improving Care Pathways for Acute Coronary Syndrome: Patients Undergoing Percutaneous Coronary InterventionAmit P Amin, John A Spertus, Hemant Kulkarni, et al.
Journal of the American College of Cardiology|May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyCarolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 14, 2013
Conversation in cardiology: should FFR and IVUS be counted as PCI?Morton Kern, Robert Applegate, Richard G Bach, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
Pageof 37